Lp(a) - Cleveland Clinic

Tag debug info: client: {"assets":{},"datasets":{},"live":{},"projects":{},"users":{},"observable":{"assets":{},"datasets":{},"live":{},"projects":{},"users":{}}}
Now: 1770521437027
Cache Key: cqdTagPageBySlug:lpa
fetchCache[cqdTagPageBySlug:lpa].expirationTime: falsey
fetchCache[cqdTagPageBySlug:lpa]. seconds remaining: falsey
All fetchCache expiration times:
-- Key: cqdNotFoundPage, seconds remaining: 6777
-- Key: cqdTagPageBySlug:robert-abouassaly, seconds remaining: -4447
-- Key: cqdPostsByTag:cqd-migrated-tag-18567,1,10, seconds remaining: -4381
-- Key: cqdTagPageBySlug:gabriel-leger, seconds remaining: -3134
-- Key: cqdPostsByTag:cqd-migrated-tag-17780,1,10, seconds remaining: -3078
-- Key: cqdTagPageBySlug:face-transplant, seconds remaining: -2037
-- Key: cqdPostsByTag:cqd-migrated-tag-896,1,10, seconds remaining: -1982
-- Key: cqdTagPageBySlug:translational-research, seconds remaining: -939
-- Key: cqdPostsByTag:cqd-migrated-tag-22665,1,10, seconds remaining: -890
-- Key: cqdTagPageBySlug:gefapixant, seconds remaining: 3228
-- Key: cqdPostsByTag:cqd-migrated-tag-26600,1,10, seconds remaining: 3284
-- Key: cqdTagPageBySlug:nerve-growth-factor, seconds remaining: 3740
-- Key: cqdPostsByTag:cqd-migrated-tag-22163,1,10, seconds remaining: 3795
-- Key: cqdTagPageBySlug:behcet-disease, seconds remaining: 5552
-- Key: cqdPostsByTag:cqd-migrated-tag-18335,1,10, seconds remaining: 5604
-- Key: cqdTagPageBySlug:peds-gi, seconds remaining: 6777
-- Key: cqdPostsByTag:cqd-migrated-tag-401,1,10, seconds remaining: 6837
-- Key: cqdTagPageBySlug:nuisance-alarms, seconds remaining: 7795
-- Key: cqdPostsByTag:cqd-migrated-tag-16957,1,10, seconds remaining: 7848
conditions:
-- false,
-- NA,
-- NA,
-- NA
-- false
Cache miss for key cqdTagPageBySlug:lpa - retrieving from Sanity
CCCache.dataFetchCount: 19074
Cache cleanup seconds remaining: 15553

Tag: Lp(a)

Lepodisiran’s Large, Durable Lp(a) Reductions in Phase 2 Trial Boost Anticipation of Phase 3 Results

Bringing More Options to Bear in CAD – Part 2: Meeting Needs of Special Patient Populations

Lipoprotein(a): Progress on One of the Last Untreatable Frontiers of Cardiovascular Risk

Novel siRNA Reduces Lipoprotein(a) by More Than 90% for 48 Weeks

Novel siRNA Therapy Lowers Elevated Plasma Lipoprotein(a) in Phase 1 APOLLO Trial

Elevated Lipoprotein(a): Is a Long-Sought Treatment Finally on the Way?